Sino Medical Sciences Technology (SHA:688108) obtained approval from a European Union regulator to reduce the regimen for its HT Supreme drug-eluting stent system, according to a Shanghai bourse filing on Thursday.
Under the approval, the stent may reduce the duration of dual antiplatelet medication to one month.
The medical device manufacturer's shares rose 1% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments